Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens

Vaccine

Volumn 34, Issue 16, 2016, Pages 1915-1926

  Volz, Asisa ^a   Lim, Stephanie ^b,c   Kaserer, Martina ^a   Lülf, Anna ^a   Marr, Lisa ^a   Jany, Sylvia ^a   Deeg, Cornelia A ^a   Pijlman, Gorben P ^d   Koraka, Penelope ^b   Osterhaus, Albert D M E ^b,c   Martina, Byron E ^b,c   Sutter, Gerd ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Artemis One Health   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Flavivirus; Poxvirus vector; Viral vaccine; West nile fever

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; WEST NILE VACCINE; WEST NILE VIRUS ENVELOPE ANTIGEN VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAMMAL CELL; MOUSE; MOUSE MODEL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; VACCINATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; WEST NILE VIRUS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CELL LINE; HORSE; HUMORAL IMMUNITY; IMMUNOLOGY; KNOCKOUT MOUSE; SECONDARY IMMUNIZATION; VACCINIA VIRUS; VIRUS LOAD; WEST NILE FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; FEMALE; HORSES; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84961057282     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.042     Document Type: Article

References (61)

1. Goldblum N., Sterk V., Paderski B. West Nile fever; the clinical features of the disease and the isolation of West Nile virus from the blood of nine human cases. Am J Hyg 1954, 59(Jan):89-103.
2. Reiter P. West Nile virus in Europe: understanding the present to gauge the future. Euro Surveill 2010, 11(Mar):19508.
3. Zeller H.G., Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean Basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis 2004, 23:147-156.
4. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the Northeastern United States. Science 1999, 286:2333-2337.
5. Murray K.O., Mertens E., Desprès P. West Nile virus and its emergence in the United States of America. Vet Res 2010, 41:67.
6. Nash D., Mostashari F., Fine A., Miller J., O'Leary D., Murray K., et al. The Outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001, 344:1807-1814.
7. Heinz F.X., Stiasny K. Flaviviruses and their antigenic structure. J Clin Virol 2012, 55:289-295.
8. Mackenzie J.M., Westaway E.G. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001, 75:10787-10799.
9. Mackenzie J.S., Williams D.T. The zoonotic flaviviruses of southern, South-Eastern and Eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health 2009, 56:338-356.
10. Karin P., Karin L., Dominik B., Ivo R., Zdenek H., Norbert N. Putative new West Nile virus lineage in Uranotaenia unguiculata Mosquitoes, Austria, 2013. Emerg Infect Dis J 2014, 20:2119.
11. Rizzoli A., Jiménez-Clavero M., Barzon L., Cordioli P., Figuerola J., Koraka P., et al. The challenge of West Nile virus in Europe: knowledge gaps and research priorities. Euro Surveill 2015, 20. pii: 21135.
12. Bakonyi T., Ivanics É., Erdélyi K., Ursu K., Ferenczi E., Weissenböck H., et al. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis 2006, 12:618-623.
13. Papa A., Bakonyi T., Xanthopoulou K., Vázquez A., Tenorio A., Nowotny N. Genetic characterization of West Nile virus lineage 2, Greece, 2010. Emerg Infect Dis 2011, 17:920-922.
14. Karaca K., Bowen R., Austgen L.E., Teehee M., Siger L., Grosenbaugh D., et al. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 2005, 23:3808-3813.
15. Minke J.M., Siger L., Cupillard L., Powers B., Bakonyi T., Boyum S., et al. Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. Vaccine 2011, 29:4608-4612.
16. Brandler S., Tangy F. Vaccines in development against West Nile virus. Viruses 2013, 5:2384-2409.
17. Ledgerwood J.E., Pierson T.C., Hubka S.A., Desai N., Rucker S., Gordon I.J., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 203:1396-1404.
18. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006, 103:6694-6699.
19. Nybakken G.E., Nelson C.A., Chen B.R., Diamond M.S., Fremont D.H. Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006, 80:11467-11474.
20. Lee J.W-M., Chu J.J-H., Ng M-L. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor αVβ3 integrin. J Biol Chem 2006, 281:1352-1360.
21. Beasley D.W.C., Whiteman M.C., Zhang S., Huang C.Y-H., Schneider B.S., Smith D.R., et al. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol 2005, 79:8339-8347.
22. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437:764-769.
23. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005, 11:522-530.
24. Kremer M., Volz A., Kreijtz J.H.C.M. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Vaccinia Virus Poxvirol Methods Protoc 2012, 2:59-93.
25. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14:1451-1458.
26. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991, 72:1031-1038.
27. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988, 106:761-771.
28. Pajot A., Michel M.-L., Fazilleau N., Pancré V., Auriault C., Ojcius D.M., et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004, 34:3060-3069.
29. Metz S.W., Geertsema C., Martina B.E., Andrade P., Heldens J.G., van Oers M.M., et al. Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Virol J 2011, 8:1-12.
30. McMurtrey C.P., Lelic A., Piazza P., Chakrabarti A.K., Yablonsky E.J., Wahl A., et al. Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proc Natl Acad Sci USA 2008, 105:2981-2986.
31. Lim S.M., Koraka P., Osterhaus A.D.M.E., Martina B.E.E. Development of a strand-specific real-time qRT-PCR for the accurate detection and quantitation of West Nile virus RNA. J Virol Methods 2013, 194:146-153.
32. Ulbert S., Magnusson S.E. Technologies for the development of West Nile virus vaccines. Future Microbiol 2014, 9:1221-1232.
33. Brandler S., Lepelley A., Desdouits M., Guivel-Benhassine F., Ceccaldi P-E., Lévy Y., et al. Preclinical studies of a Modified Vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 2010, 84:5314-5328.
34. Kreijtz J.H.C.M., Goeijenbier M., Moesker F.M., van den Dries L., Goeijenbier S., De Gruyter H.L.M., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014, 14:1196-1207.
35. Kreijtz J.H.C.M., Suezer Y., de Mutsert G., van den Brand J.M.A., van Amerongen G., Schnierle B.S., et al. Preclinical evaluation of a Modified Vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009, 27:6296-6299.
36. Kreijtz J.H.C.M., Suezer Y., de Mutsert G., van den Brand J.M.A., van Amerongen G., Schnierle B.S., et al. Recombinant Modified Vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009, 199:405-413.
37. Kreijtz J.H.C.M., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant Modified Vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007, 195:1598-1606.
38. Rory, Heidi L.M.D.G., Theo M.B., Mark P., Ron A.M.F., Albert D.M.E.O., et al. Induction of influenza (H5N8) antibodies by Modified Vaccinia virus Ankara H5N1 vaccine. Emerg Infect Dis J 2015, 21:1086.
39. de Vries R.D., De Gruyter H.L.M., Bestebroer T.M., Pronk M., Fouchier R.A.M., Osterhaus A.D.M.E., et al. Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine. Emerg Infect Dis 2015, 21:1086-1088.
40. Falconar A. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 1999, 144:2313-2330.
41. Diamond M.S., Pierson T.C., Fremont D.H. The structural immunology of antibody protection against West Nile virus. Immunol Rev 2008, 225:212-225.
42. Pupo-Antúnez M., Vázquez S., Sosa A.L., Caballero Y., Vásquez Y., Morier L., et al. Monoclonal antibody against Saint Louis encephalitis prM viral protein. J Virol Methods 2015, 218:14-18.
43. Allison S.L., Stadler K., Mandl C.W., Kunz C., Heinz F.X. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 1995, 69:5816-5820.
44. Delenda C., Frenkiel M., Deubel V. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Arch Virol 1994, 139:197-207.
45. Venugopal K., Shiu S.Y.W., Gould E.A. Recombinant vaccinia virus expressing PrM and E Glycoproteins of louping ill virus: induction of partial homologous and heterologous protection in mice. Res Vet Sci 1994, 57:188-193.
46. Nzonza A., Lecollinet S., Chat S., Lowenski S., Mérour E., Biacchesi S., et al. A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice. PLoS ONE 2014, 9:e91766.
47. Roldão A., Mellado M.C.M., Castilho L.R., Carrondo M.J.T., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9:1149-1176.
48. Davis B.S., Chang G-J.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001, 75:4040-4047.
49. Desprès P., Combredet C., Frenkiel M-P., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191:207-214.
50. Hanna S.L., Pierson T.C., Sanchez M.D., Ahmed A.A., Murtadha M.M., Doms R.W. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J Virol 2005, 79:13262-13274.
51. Takahashi H., Ohtaki N., Maeda-Sato M., Tanaka M., Tanaka K., Sawa H., et al. Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus. Microb Infect 2009, 11:1019-1028.
52. Zhang Y., Kaufmann B., Chipman P.R., Kuhn R.J., Rossmann M.G. Structure of immature West Nile virus. J Virol 2007, 81:6141-6145.
53. Lindenbach B.D., Rice C.M. Molecular biology of flaviviruses. Advances in virus research 2003, 23-61. Academic Press, New York.
54. Wang P-G., Kudelko M., Lo J., Siu L.Y.L., Kwok K.T.H., Sachse M., et al. Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS ONE 2009, 4:e8325.
55. Parsons R., Lelic A., Hayes L., Carter A., Marshall L., Evelegh C., et al. The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes. J Immunol 2008, 181:1563-1572.
56. De Filette M., Ulbert S., Diamond M.S., Sanders N.N. Recent progress in West Nile virus diagnosis and vaccination. Vet Res 2012, 43:1-15.
57. Brien J.D., Uhrlaub J.L., Nikolich-Žugich J. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J Immunol 2008, 181:8568-8575.
58. Netland J., Bevan J.M. CD8 and CD4 T cells in West Nile virus immunity and pathogenesis. Viruses 2013, 5:2573-2584.
59. Brien J.D., Uhrlaub J.L., Nikolich-Žugich J. Protective capacity and epitope specificity of CD8+ T cells responding to lethal West Nile virus infection. Eur J Immunol 2007, 37:1855-1863.
60. Shrestha B., Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004, 78:8312-8321.
61. Brien J.D., Uhrlaub J.L., Hirsch A., Wiley C.A., Nikolich-Žugich J. Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med 2009, 206:2735-2745.